ZIOPHARM Oncology (ZIOP) Gets U.S. Patent Covering Anti-Tumor Methods Used in ZIO-201

Article Stock Quotes (1) Comments (0)

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the United States Patent and Trademark Office issued Patent No. 8,232,262 entitled "Salts of Isophosphoramide Mustard and Analogs Thereof as Anti-Tumor Agents" with claims directed to pharmaceutical compositions, methods of treatment and methods of making a novel DNA cross-linker, including palifosfamide (ZIO-201). This newly issued patent provides subject matter exclusivity through 2027. The patent estate covering palifosfamide compositions, formulations, methods of use and methods of manufacture now includes issued patents in the United States, Australia, Europe, New Zealand and South Africa, as well as pending applications in the United States and various foreign jurisdictions.

ZIOPHARM is evaluating palifosfamide in an international, randomized, double-blinded, placebo-controlled Phase 3 trial in first-line metastatic soft tissue sarcoma referred to as the PICASSO 3 Study. The Company is also evaluating palifosfamide in a pivotal Phase 3 study in first-line metastatic small cell lung cancer. Orphan Drug Designation for the treatment of soft tissue sarcoma has been obtained for palifosfamide in both the United States and the European Union.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Tessera (TSRA), Starboard Reach Agreement Over Board Composition
• Gleacher & Co. (GLCH) Reports Election of Five for Board Members

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?